SMi's 4th Annual Pain Therapeutics (K73)

Venue: The Hatton, London

Location: London, United Kingdom

Event Date/Time: Jun 11, 2003 End Date/Time: Jun 12, 2003
Report as Spam

Description

“Growth of the analgesia market is dependent on the introduction of new products. The future of pain therapeutics is bright and the opportunity for investment, biotechnology and pharmaceutical companies to partner in value creation is significant”
Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

SMi’s 4th Annual Conference...
Pain Therapeutics
11th & 12th June 2003, The Hatton, London

A unique opportunity to learn from leading industry experts including:
Dr Roy Bullingham, Vice President, Global Clinical Pharmacology, Pharmacia/Pfizer
Dr Peter McIntyre, Laboratory Head/Program Team Head, Novartis
Prof Odd-Geir Berge, Associate Director, In Vivo Pharmacology, AstraZeneca
Dr Mark Field, Manager, Pain Therapeutics, Pfizer
Kirk Johnson, Head, Neuroscience Research, Eli Lilly
Dr Theo Meert, Disease Area Head & Research Fellow, CNS Pain & Alzheimer, Johnson & Johnson
Dr Kirsten Arndt, Head, Laboratory, CNS Research, Boehringer Ingelheim
Dr Hans Quiding, Senior Research Scientist, AstraZeneca
Dr Steven England, Principal Scientist, Pfizer
Dr Katharine Walker, Director, Neuropharmacology, Purdue Pharma
Dr Gordon Ng, Research Scientist, Neurology, Amgen

Benefits of attending:
ADVANCES IN PAIN THERAPEUTICS: keep up to date with the very latest research
HUMAN/ANIMAL MODELS: understand the need for effective modelling systems
DRUG DISCOVERY: find out about possible new targets for treating pain
TARGET VALIDATION: look at novel techniques for validating potential targets
CLINICAL TRIALS: learn about new approaches to clinical study design
MARKET OPPORTUNITIES: discover the key factors for success of emerging therapies
Day One – 11th June 2003

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Dr Richard Carter, Managing Director, NeuroBioMedica

OPPORTUNITIES IN PAIN THERAPEUTICS
9.10 Overview
 Market opportunity
 Issues with existing therapies
 Unmet medical need
 Key factors for success
 Emerging therapies
 The future for pain relief
Dr Steven England, Principal Scientist, Pfizer

TRP CHANNEL THERMORECEPTORS AS TARGETS FOR CHRONIC PAIN
9.40 TrpV1 blockers and chronic pain
 The TrpV1 blocker capsazepine (CPZ) shows species selectivity with respect to some of its actions
 CPZ is anti-hyperalgesic when assayed in a susceptible species
 Other TrpV1 blockers may be anti-hyperalgesic
 We and others have discovered other Trp channel thermoreceptors in sensory neurones and skin
 The possibility that these may be involved in pain sensation
Dr Peter McIntyre, Laboratory Head/Program Team Head, Novartis

TARGET VALIDATION FOR NEW ANALGESIC TARGETS
10.20 Genetic approaches
 Targeted gene deletion
 Peripheral vs central targets
 Sodium channels and pain pathways
Prof John Wood, Professor, Molecular Neuroscience, University College London

11.00 Morning Coffee

PRECLINICAL MODELS
11.20 The need for good preclinical models
 Challenges in developing preclinical models
 From simple to complex models of pain
 Measuring clinically relevant symptoms
 How effective are preclinical models?
Dr Mark Field, Manager, Pain Therapeutics, Pfizer

ANIMAL PAIN MODELS
12.00 The need for good animal models
 General discussion: validity of animal models
 Difficulties in assessing pain in animals
 How effective are animal models?
 The use of animals to screen putative analgesics
 Animals models to investigate the causes of pain
Prof Odd-Geir Berge, Associate Director, In Vivo Pharmacology, AstraZeneca

12.40 Networking Lunch






CHRONIC PAIN AND BONE DISEASE
1.40 Chronic pain associated with bone cancer and osteoarthritis
 Clinical perspectives on chronic pain associated with bone disease
 Existing therapies
 Unmet medical needs
 Pre-clinical models of chronic 'bone-related' pain
Dr Katharine Walker, Director, Neuropharmacology, Purdue Pharma

HUMAN EXPERIMENTAL PAIN MODELS
2.20 Discussion on why and how
 Why human experimental pain models?
 Examples of pain models
 Examples of variables in pain models
 Examples of drug effects in pain models
Dr Hans Quiding, Senior Research Scientist, AstraZeneca

OPIOID ANALGESICS
3.00 How to increase the efficacy and tolerability of opioids
 Comparison of opioids
 Role of routes of administration/techniques
 Combination treatments to reduce opioid requirements
 Reducing opioid side-effects
Dr Theo Meert, Disease Area Head & Research Fellow, CNS Pain & Alzheimer, Johnson & Johnson

3.40 Afternoon Tea

OPIOIDS
4.00 The use of opioids for the treatment of chronic pain
 Effectiveness of opioids
 Advantages and disadvantages with opioids
 The success of opioid pain relievers
 New generation of opioid painkillers
 Alleviating the side-effects of traditional opioid narcotics
Dr Christine Rauschkolb, Associate Director, Therapeutic Area Neurology, Schwarz BioSciences

CANNABIS-BASED MEDICINES
4.40 The use of cannabis-based medicines in the treatment of pain
 Clinical trials of cannabis-based medicines in pain
 Safety of cannabis-based medicines
 The place of cannabis-based medicines in the management of pain
Dr Nicos Sarantis, Clinical Development Director, GW Pharmaceuticals

TOPICAL APPROACHES TO THE MANAGEMENT OF NEUROPATHIC PAIN
5.20 Cutaneous nociceptors and chronic pain conditions
 Role of cutaneous nociceptors in pain initiation and maintenance
 Central versus peripheral mechanisms
 Topical lidocaine-based therapies
 Topical capsaicin-based therapies
 Recent clinical data
Dr Keith Bley, Senior Vice President, Nonclinical Research & Development, NeurogesX

6.00 Chairman’s Closing Remarks and Close of Day One






Day Two – 12th June 2003

8.30 Re-registration & Coffee

9.00 Chairman's Opening Remarks
Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

MIGRAINE
9.10 Preclinical identification of novel, potential migraine therapies
 Pathophysiology of migraine
 Animal models of migraine
 Current migraine therapies and pharmacological tools
 Using animal models to predict novel therapies
 Emerging therapies
Kirk Johnson, Head, Neuroscience Research, Eli Lilly

MIGRAINE PAIN: THE ROLE OF CGRP
9.40 The therapeutic potential of CGRP - antagonists
 Migraine pathophysiology
 Current treatment
 The role of vasodilation in migraine
 The neuropeptide CGRP and its receptors
 In vitro and in vivo pharmacological profile of BIBN4096, a potent CGRP receptor antagonist
Dr Kirsten Arndt, Head, Laboratory, CNS Research, Boehringer Ingelheim

NEW APPROACHES TO INFLAMMATORY AND NEUROPATHIC PAIN
10.20 The potent nonapeptide analgesic, Syn1002
 Decreases mechanical and thermal hyperalgesia
 Reduces pro-inflammatory cytokine levels induced by endotoxin challenge
 Reduces mechanical allodynia and heat hyperalgesia in CCI and SNI models
 Reduces capsaicin induced pain-related behaviour
Prof Anthony Rees, Director, Science, Synt:em & Dr Bared Safieh-Garebedian, Associate Professor, American University of Beirut, Lebanon

11.00 Morning Coffee

CLINICAL TRIALS FOR PAIN: MODELS AND MUDDLES
11.20 Therapeutic needs and drug development
 The role of preclinical models
 The clinical analgesic assay
 Issues with the models: some examples
 The therapeutic gap
 New approaches to some of the issues
Dr Roy Bullingham, Vice President, Global Clinical Pharmacology, Pharmacia/Pfizer

CHANGING CONCEPTS IN ANALGESIC CLINICAL RESEARCH
12.00 New approaches to clinical study design and outcome assessments
 Acute and chronic pain models that are relevant to clinical practice
 Regulatory trends in analgesic clinical evaluation
 The shift to more relevant clinical outcome measures
 Tiered responder analysis in pain treatment assessment
 The future: mechanism-sensitive/specific outcome measures
Dr Mason Diamond, Senior Vice President, Operations & Business Development, Ingenium Research

12.40 Networking Lunch

BIOMARKERS IN PAIN RESEARCH
1.40 Biomarkers for target assessment
 Rodent pain models for target validation
 Identifying biomarkers for pain targets
 Imaging, skin and blood biomarker assays
 Application of biomarkers for preclinical development
 Application of biomarkers in the clinic
Dr Gordon Ng, Research Scientist, Neurology, Amgen

VALIDATING DRUG TARGETS FOR PAIN IN MAN
2.20 Clinical studies in human pain states
 Lessons from failed clinical trials
 Limitations of volunteer models
 Relating neuropathology of novel targets to function in humans
 Selecting patients and end-points based on target validation
 Value of ‘experimental’ Phase IIa trials
Prof Praveen Anand, Professor, Clinical Neurology, Imperial College London

CURRENT REGULATORY INITIATIVES IN ANALGESIA
3.00 Impact on drug development
 Review current state of analgesic drug development
 Identify current regulatory and scientific initiatives
 Challenges in analgesic drug development
 Potential solutions to current challenges
Dr Najib Babul, Chief Executive Officer, TheraQuest Biosciences

3.40 Afternoon Tea

DRUG DISCOVERY AND DEVELOPMENT
4.00 Case study: Ionix
 Investing in new classes of analgesic drugs
 Building a balanced risk product portfolio
 Establishing partnerships to drive development
 Commercialisation opportunities
Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

INTRANASAL DRUG DELIVERY FOR PAIN THERAPEUTICS
4.40 The unique advantages to intranasal delivery of pain therapeutics
 Very fast onset of action
 Absence of first pass metabolism
 Potential for preferential CNS delivery
 Needleless delivery
The advantages of Nastech’s formulation science
 High-throughput in vitro screening systems to evaluate safety and efficacy of candidate formulations
 Ongoing research into the molecular biology of tight junction modulation
 20 years work developing proprietary intranasal formulations
Dr Gordon Brandt, Executive Vice President, Science & Clinical Development, Nastech Pharmaceuticals

MARKET OPPORTUNITIES IN CHRONIC LOWER BACK PAIN
5.20 For those of you not lifting properly!
 Epidemiology of CLBP
 Current therapy and unmet needs
 Drug development activity
 Market outlook
 Key challenges and opportunities
Dr Nancy MacDonald, Analyst, Decision Resources

6.00 Chairman's Closing Remarks and Close of Conference

Venue